Xeris Biopharma Holdings Inc (XERS) News

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over...

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and...

Xeris to Participate in Upcoming Investor Conferences

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to...